Ο επίσημος ιστότοπος της Pfizer τα λέει όλα.

Στο επίσημο σαιτ της Pfizer, cvdvaccine-us.com, που μπήκαμε λέει τα εξής για τις παρενέργειες των εμβολίων.

Υποχρεωτικές απαιτήσεις για τη χορήγηση εμβολίων Pfizer-BioNTech COVID-19 υπό εξουσιοδότηση έκτακτης ανάγκης. Προκειμένου να μετριαστούν οι κίνδυνοι από τη χρήση αυτού του μη εγκεκριμένου προϊόντος υπό την Εξουσιοδότηση Χρήση Έκτακτης Ανάγκης (EUA, Emergency Use Authorization) και να βελτιστοποιηθεί το πιθανό όφελος του εμβολίου Pfizer-BioNTech COVID-19, απαιτούνται τα ακόλουθα στοιχεία. Η χρήση μη εγκεκριμένου εμβολίου Pfizer-BioNTech COVID-19 για ενεργό ανοσοποίηση για την πρόληψη του COVID-19 βάσει αυτής της EUA περιορίζεται στα ακόλουθα (πρέπει να πληρούνται όλες οι απαιτήσεις):…

Ο πάροχος εμβολιασμού είναι υπεύθυνος για την απάντηση σε αιτήματα της FDA για πληροφορίες σχετικά με σφάλματα χορήγησης εμβολίων, ανεπιθύμητες ενέργειες, περιπτώσεις MIS σε ενήλικες και παιδιά και περιπτώσεις COVID-19 που έχουν ως αποτέλεσμα νοσηλεία ή θάνατο μετά τη χορήγηση του εμβολίου Pfizer-BioNTech V 19 στους παραλήπτες.

* Οι σοβαρές ανεπιθύμητες ενέργειες ορίζονται ως:

• Θάνατος
• Ένα απειλητικό για τη ζωή ανεπιθύμητο συμβάν
• Νοσηλεία σε νοσοκομείο ή παράταση της υπάρχουσας νοσηλείας.
• Μια επίμονη ή σημαντική ανικανότητα ή ουσιαστική διαταραχή της ικανότητας διεξαγωγής κανονικών λειτουργιών ζωής
• Μια συγγενής ανωμαλία / γενετικό ελάττωμα
• Ένα σημαντικό ιατρικό συμβάν που, βάσει της καταλλήλου ιατρικής κρίσεως, μπορεί να θέσει σε κίνδυνο το άτομο και μπορεί να απαιτήσει ιατρική ή χειρουργική επέμβαση για την αποτροπή ενός από τα αποτελέσματα που αναφέρονται παραπάνω.

Και ο νοών νοείτω… https://capnews.me

 COVID-19 Vaccine 

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Click here for virtual assistant support

Adverse Event Reporting 

Report an Adverse Event to VAERS*

*This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of this site. 

Report an Adverse Event to Pfizer 

Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use Authorization

In order to mitigate the risks of using this unapproved product under EUA and to optimize the potential benefit of Pfizer-BioNTech COVID-19 Vaccine, the following items are required. Use of unapproved Pfizer-BioNTech COVID-19 Vaccine for active immunization to prevent COVID-19 under this EUA is limited to the following (all requirements must be met):

1. Pfizer-BioNTech COVID-19 Vaccine is authorized for use in individuals 12 years of age and older.
2. The vaccination provider must communicate to the individual receiving the Pfizer‑BioNTech COVID-19 Vaccine or their caregiver, information consistent with the “Fact Sheet for Recipients and Caregivers” prior to the individual receiving Pfizer‑BioNTech COVID‑19 Vaccine.
3. The vaccination provider must include vaccination information in the state/local jurisdiction's Immunization Information System (IIS) or other designated system.
4. The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):
• vaccine administration errors whether or not associated with an adverse event,
• serious adverse events† (irrespective of attribution to vaccination),
• cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and
• cases of COVID-19 that result in hospitalization or death.

Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words “Pfizer‑BioNTech COVID‑19 Vaccine EUA” in the description section of the report.

5. The vaccination provider is responsible for responding to FDA requests for information about vaccine administration errors, adverse events, cases of MIS in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of Pfizer-BioNTech COVID‑19 Vaccine to recipients.

†Serious adverse events are defined as:

• Death;
• A life-threatening adverse event;
• Inpatient hospitalization or prolongation of existing hospitalization;
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
• A congenital anomaly/birth defect;
• An important medical event that based on appropriate medical judgement may jeopardize the individual and may require medical or surgical intervention to prevent one of the outcomes listed above.

Other Adverse Event Reporting to VAERS and Pfizer Inc.

Vaccination providers may report to VAERS other adverse events that are not required to be reported using the contact information above.

To the extent feasible, report adverse events to Pfizer Inc. using the contact information below or by providing a copy of the VAERS form to Pfizer Inc.

Website

www.pfizersafetyreporting.com

Fax number

1-866-635-8337

Telephone number

1-800-438-1985

---

• Important Safety Information

  • Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine
  • Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine

    Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html)

  • Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting
  • Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine
  • The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients
  • In clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%)
  • In a clinical study, adverse reactions in adolescents 12 through 15 years of age included pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), injection site redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%)
  • Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions, diarrhea, vomiting, and pain in extremity (arm) have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine outside of clinical trials

    Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 Vaccine

  • Available data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy
  • Data are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretion
  • There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series
  • Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. The reports should include the words “Pfizer-BioNTech COVID-19 Vaccine EUA” in the description section of the report
  • Vaccination providers should review the Fact Sheet for Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use Authorization
  • Before administration of Pfizer-BioNTech COVID-19 Vaccine, please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine-us.com

---

Ensuring the Authenticity of Pfizer-BioNTech COVID-19 Vaccine

• Pfizer is committed to patient safety and ensuring that people have accurate information about the investigational Pfizer-BioNTech COVID-19 Vaccine, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate Pfizer-BioNTech COVID-19 Vaccines to protect patients from products that might be dangerous and lead to serious and life-threatening harm
• The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Pfizer-BioNTech COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 12 years of age and older.

  • The Pfizer-BioNTech COVID-19 Vaccine is only administered intramuscularly by a healthcare professional
  • The Pfizer-BioNTech COVID-19 Vaccine is not taken orally and is not available in a capsule or tablet form
• Authentic Pfizer-BioNTech COVID-19 Vaccines, manufactured by Pfizer Inc., will include the Pfizer and BioNTech names on the label and are dispensed in a vial with a purple cap
• Ensure the safety of the vaccine vials by limiting access to only authorized personnel. The location they are stored in must be secure and locked when not in use. To prevent counterfeits, discard vaccine vials in sharps containers and empty vial trays as medical waste or deface or safely crush all materials so they cannot be reused. Remember, Pfizer-BioNTech COVID-19 Vaccines are only available through government-authorized vaccination centers – such as hospitals, outpatient clinics, pharmacies, and community vaccination locations. The Pfizer-BioNTech COVID-19 Vaccine can only be administered by licensed healthcare professionals, or other individuals that are approved vaccinators, at government-authorized vaccination sites. Individual doses are not for sale

If you suspect the Pfizer-BioNTech COVID-19 Vaccine you have purchased may be counterfeit, contact us at 1-800-438-1985 or visit https://www.pfizer.com/products/product-contact-information.

To learn more, visit https://www.pfizer.com/counterfeiting/frequently-asked-questions.

===================== "O σιωπών δοκεί συναινείν"